Company profile
VolitionRX Ltd
AMEX: VNRX · Healthcare · Medical - Devices
#821 of 1,422 Healthcare companies by revenuetop-quartile growth
EA Score
40DFH 18DQ 59GM 62SS 53
v0.1 · 65/100 weight · provisional
↑ 3-yr revenue growth, disclosure history · ↓ balance-sheet leverage, return on assets
Methodology →Revenue TTM
$2.5M
Rev growth YoY (TTM)
+86.3%
Net income (FY)
-$23.4M
Employees
75
as of 2026-08-22
Market cap
$3.5M
as of 2026-08-22
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.7M$1.7M2025
Net income-$23.4M-$23.4M2025
Operating income-$21.7M-$21.7M2025
Total assets$6.9M$6.9M2025
Liabilities$42.5M$42.5M2025
Equity-$34.2M-$34.2M2025
Revenue trend
FY2014 – FY2025 · USD
FY14
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is VolitionRX Ltd’s revenue?
VolitionRX Ltd booked $1.7M in FY2025 revenue, growing 40% year over year — faster than most Healthcare companies we track, at a -1352.2% net margin.
Peers · Healthcare
Nutranomics, Inc.——CanaFarma Hemp Products Corp.——Spectral Medical Inc31DClearside Biomedical, Inc.——Rani Therapeutics Holdings, Inc.41DEBR Systems, Inc.34DNeighbors
Clark →Key facts
CEOCameron Reynolds
SectorHealthcare
IndustryMedical - Devices
HeadquartersHenderson, NV
ExchangeAMEX: VNRX
Employees75
IPO date2012-03-02
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.